Drreddys Laboratories | RDY - Selling And Administration Expenses


Drreddys Laboratories reported INR14.47B in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
ANI Pharmaceuticals USD 91.66M 18.01M Jun/2026
Aurora Cannabis CAD 41.4M 781K Mar/2026
Bayer EUR 3.96B 267M Jun/2026
Canopy Growth CAD 31.17M 2.27M Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
Corcept Therapeutics USD 156.9M 28.85M Jun/2026
Drreddys Laboratories INR 14.47B 12.45B Mar/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Novartis USD 3.24B 101M Jun/2026
Pacira USD 91.81M 7.93M Jun/2026
Phibro Animal Health USD 78.32M 10.24M Dec/2025
Prestige Brands USD 43.3M 13.02M Jun/2026
Richter Gedeon HUF 55.32B 3.03B Mar/2026
Sun Pharmaceuticals INR 24.89B 637.6M Mar/2025
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
Teva Pharmaceutical Industries USD 1.03B 34M Jun/2026